Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies
Trastuzumab deruxtecan (T-DXd) is approved for HER2-low (HER2 immunohistochemistry (IHC)1+ or 2+ with non-amplified in situ hybridization (ISH)), b…
